09/08/23 Biospectra, Inc. and BioSpectra Canada, Ltd completed the acquisition of Polydex Pharmaceuticals Limited (OTCPK:POLX.F). CI
15/06/23 Polydex Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended April 30, 2023 CI
02/05/23 Polydex Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended January 31, 2023 CI
27/04/23 Biospectra, Inc. and BioSpectra Canada, Ltd entered into an agreement to acquire Polydex Pharmaceuticals Limited (OTCPK:POLX.F) for $6.9 million. CI
16/12/22 Polydex Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022 CI
15/12/22 Earnings Flash (POLXF) POLYDEX PHARMACEUTICALS LIMITED Reports Q3 Revenue $858,089 MT
15/12/22 Earnings Flash (POLXF) POLYDEX PHARMACEUTICALS LIMITED Reports Q3 Loss $-0.11 MT
15/09/22 Polydex Pharmaceuticals Limited Reports Earnings Results for the Second Quarter Ended July 31, 2022 CI
15/06/22 Polydex Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended April 30, 2022 CI
15/06/22 Earnings Flash (POLXF) POLYDEX PHARMACEUTICALS LIMITED Posts Q1 Revenue $1.2M MT
02/05/22 Polydex Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended January 31, 2022 CI
02/05/22 Polydex Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended January 31, 2022 CI
26/01/22 Polydex Pharmaceuticals Limited Enters into an Agreement with Termanox Water Treatment Solutions for A Novel Use of Its Native Dextran Product CI
Manager TitleAgeSince
Chief Executive Officer 67 01/01/1996
Director of Finance/CFO 60 01/11/2018
Chief Operating Officer 73 01/01/1984
Director TitleAgeSince
Chairman 67 27/01/1998
Director/Board Member 86 01/01/1983
Director/Board Member 83 01/01/1998
Change 5-day change 1-year change 3-year change Capi.($)
+4.08%+4.08% - - 6.82M
+3.90%+9.86%+96.91%+136.30% 1,098B
+0.99%+2.91%+51.05%+52.06% 631B
+0.78%+1.17%+25.21%+63.74% 438B
+0.08%+4.33%+51.52%+40.75% 368B
+0.22%+2.28%+32.72%+40.38% 298B
+0.21%+2.25%+8.77%+8.83% 251B
+1.52%+10.12%+44.75%+59.20% 226B
+0.89%+0.37%-4.29%-50.25% 209B
-0.11%+1.46%+11.43%+66.32% 165B
Average +0.75%+1,657.21%+35.34%+46.37% 409.37B
Weighted average by Cap. +0.30%+1,331.50%+52.02%+68.80%
Logo Polydex Pharmaceuticals Limited
Polydex Pharmaceuticals Limited is a company, which is engaged in the development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market. The Company also manufactures bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry. It focuses on the manufacture and sale of Dextran and derivative products, including Iron Dextran and Dextran Sulphate, and other specialty chemicals. The Company's products include Iron Dextran and Dextran Sulphate. The Company sells Iron Dextran to independent distributors and wholesalers primarily in Europe, the Far East, South America and Canada. Iron Dextran is a derivative of Dextran produced by complexing iron with Dextran. Iron Dextran is injected into pigs at birth as a treatment for anemia. Dextran Sulphate manufactured by the Company is sold primarily to independent distributors, or direct to companies in the United States and Europe for analytical applications.
Employees
-